Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

BACKGROUND: CC chemokine receptor 4 (CCR4), the receptor for CCL22 and CCL17, is expressed on the surface of effector Tregs that have the highest suppressive effects on antitumor immune response. CCR4 is also widely expressed on the surface of tumor cells from patients with adult T-cell leukemia/lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ting, Sun, Jing, Li, Jinying, Zhao, Yunuo, Zhang, Tao, Yang, Ruoning, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157723/
https://www.ncbi.nlm.nih.gov/pubmed/34039310
http://dx.doi.org/10.1186/s12885-021-08363-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157723/
https://www.ncbi.nlm.nih.gov/pubmed/34039310
http://dx.doi.org/10.1186/s12885-021-08363-w

Ejemplares similares